Esteban Urias
Appearances
- DateMay 8, 2023BACKGROUND: The glucagon-like-receptor (GLP)-1 agonist semaglutide has demonstrated therapeutic efficacy on clinical endpoints in a recent phase 2 clinical trial in patients with non-alcoholic steatohepatitis (NASH)(Newsome et al. NEJM, 2021)…
Presenter
Speakers
University of Michigan Medical School - DateMay 6, 2023The rising prevalence of non-alcoholic fatty liver disease (NAFLD) will result in increased referrals to gastroenterology and hepatology units…
Presenter
Speakers
University of Michigan Medical School